Finally, it is worth noting that the PARP inhibitor olaparib has a more favorable effect on BRCA1-mutated patients in the clinical treatment of breast cancer, but the BRCA1-mutated patients account for only a portion of the population. Here, BRCA1 is linked to breast cancer.